By Counterforce Health Team in Waylivra (volanesorsen) —

How to Get Waylivra (Volanesorsen) Covered by Aetna CVS Health in Washington: Appeals Guide and Medical Necessity Process

Waylivra (volanesorsen) is not FDA-approved in the US and requires a medical necessity appeal through Aetna CVS Health rather than standard prior authorization. In Washington, you'll need genetic confirmation of familial chylomicronemia syndrome (FCS), documented failure of FDA-approved alternatives like Tryngolza, and a specialist letter detailing clinical rationale. If denied, Washington's external review process through the Office of the Insurance Commissioner provides binding decisions within 20-30 days. First step: Contact your lipid specialist to gather FCS genetic testing results and triglyceride levels ≥880 mg/dL.

Table of Contents

Coverage Requirements at a Glance

Requirement What It Means Documentation Needed Timeline
FCS Diagnosis Genetic confirmation of familial chylomicronemia syndrome Biallelic mutations in LPL, APOC2, APOA5, LMF1, or GPIHBP1 genes Genetic test results
Triglyceride Levels Persistent severe hypertriglyceridemia ≥880 mg/dL on multiple fasting measurements Recent lab work (within 30 days)
Prior Therapy Failure Inadequate response to standard treatments Documentation of fibrates, omega-3s, statins trials Treatment history notes
Specialist Involvement Lipidologist or endocrinologist prescription Letter detailing clinical rationale and monitoring plan Specialist consultation
Medical Necessity Review Appeal process for non-formulary drug Complete clinical package submission 30-45 days standard review

Step-by-Step: Medical Necessity Appeal Process

1. Verify Your Aetna Plan Details

Call Aetna member services at 1-866-235-5660 to confirm your specific plan's medical exception process and required forms. CVS Caremark handles most specialty medications for Aetna plans.

2. Gather Essential Clinical Documentation

Work with your healthcare team to compile:

  • Genetic testing results confirming FCS diagnosis
  • Triglyceride levels ≥880 mg/dL from multiple fasting measurements
  • Treatment history documenting failures or contraindications to FDA-approved alternatives
  • Specialist consultation notes from lipidologist or endocrinologist

3. Calculate FCS Diagnostic Scores

Have your specialist document either:

  • North American FCS Score ≥45 (indicating "likely FCS" or "definite FCS")
  • Moulin Score ≥10 (indicating FCS is very likely)

4. Submit Medical Necessity Request

Submit through:

  • Aetna Provider Portal (preferred method for healthcare providers)
  • CoverMyMeds platform for electronic prior authorization
  • Fax submission to your plan's specialty pharmacy department (verify current fax number with member services)

5. Request Expedited Review if Applicable

For triglycerides >1,000 mg/dL or recent pancreatitis history, request expedited review with clinical urgency documentation. Standard timeline is 72 hours for urgent cases.

6. Prepare for Peer-to-Peer Review

If initially denied, your specialist can request a peer-to-peer consultation with Aetna's medical director to discuss patient-specific clinical data and treatment rationale.

7. Enroll with CVS Specialty if Approved

Upon approval, contact CVS Specialty at 1-800-237-2767 or visit CVSspecialty.com to coordinate medication delivery and monitoring.

Working with Your Doctor: Essential Documentation

Pre-Visit Preparation

Before your specialist appointment, prepare a comprehensive symptom and treatment timeline:

  • Symptom onset: Age when severe hypertriglyceridemia was first detected
  • Pancreatitis history: Dates of acute episodes, hospitalizations, emergency visits
  • Treatment trials: Complete list of lipid-lowering medications tried, doses, duration, and reasons for discontinuation
  • Family history: Relatives with high triglycerides or pancreatitis
  • Functional impact: How FCS symptoms affect daily activities and quality of life

Clinical Evidence Package

Your healthcare provider will need to document:

Diagnostic Confirmation:

  • Genetic testing results showing biallelic pathogenic variants in FCS genes
  • Apolipoprotein B levels (typically <100 mg/dL in FCS)
  • Exclusion of secondary causes (thyroid function, diabetes, kidney disease)

Treatment Response History:

  • Maximum tolerated doses of fibrates with triglyceride response
  • Omega-3 fatty acid trials (prescription-strength EPA/DHA)
  • Statin therapy attempts and tolerability
  • Dietary modifications and nutritionist consultations

Clinical Severity Markers:

  • Recurrent pancreatitis episodes despite standard therapy
  • Triglyceride levels persistently above 880 mg/dL
  • Presence of eruptive xanthomas or lipemia retinalis
  • Impact on cardiovascular risk assessment

Medical Necessity Letter Components

Your specialist's letter should include these essential elements:

Clinical Rationale Section

  • Patient identification: Age, diagnosis confirmation method, genetic test results
  • Disease severity: Specific triglyceride levels, pancreatitis frequency, symptom impact
  • Treatment history: Detailed account of prior therapy trials, maximum tolerated doses, reasons for inadequacy
  • Waylivra rationale: Why this antisense oligonucleotide mechanism offers unique benefits for this patient's FCS

Supporting Evidence

  • European approval data: Reference EMA approval for FCS patients with inadequate response to standard therapy
  • Clinical trial data: APPROACH study showing 57% triglyceride reduction
  • Safety monitoring plan: Proposed schedule for platelet count and renal function monitoring
  • Treatment goals: Specific triglyceride targets and pancreatitis prevention objectives

Professional Guidelines References

Include citations from:

  • Endocrine Society Clinical Practice Guidelines for lipid disorders
  • European guidelines for FCS management
  • Published consensus statements on rare lipid disorders
  • Peer-reviewed literature on volanesorsen efficacy and safety
From our advocates: We've seen medical necessity appeals succeed when specialists emphasize the unique mechanism of action—Waylivra targets APOC3 mRNA directly, which differs fundamentally from other lipid-lowering approaches. Including specific genetic test results and quantified treatment failures strengthens the clinical rationale significantly.

Common Denial Reasons and Solutions

Denial Reason Rebuttal Strategy Required Documentation
Not FDA-approved Invoke medical necessity exception; reference European approval EMA approval documents, clinical guidelines
Experimental/investigational Document established international use and safety profile Published studies, prescribing information
Alternatives available Prove FDA-approved options inappropriate or ineffective Tryngolza failure documentation, contraindications
Insufficient clinical documentation Submit complete FCS diagnostic workup Genetic testing, specialist consultation, treatment history
Not medically necessary Detail disease severity and treatment urgency Pancreatitis history, triglyceride trends, quality of life impact

Washington Appeals Process

Washington state provides robust consumer protections for insurance denials through structured internal and external review processes.

Internal Appeal Timeline

  • First-level internal appeal: File within 180 days of denial
  • Review timeline: 30 days for standard review, 72 hours for expedited cases
  • Required documentation: Original denial letter, additional clinical evidence, specialist rebuttal

External Review Rights

If internal appeals are unsuccessful, Washington residents can request external review through the Office of the Insurance Commissioner (OIC).

Key External Review Details:

  • Deadline: 60 days from final internal denial for fully-insured plans
  • Review timeline: 20 days for standard cases, 72 hours for expedited
  • Decision authority: Independent Review Organization (IRO) with binding decisions
  • Cost: No fee to patient; insurer pays IRO costs

OIC Consumer Support

The Washington Insurance Commissioner's office provides direct consumer assistance:

  • Consumer Advocacy line: 1-800-562-6900
  • Online resources: Appeal guidance and template letters available
  • Complaint process: File complaints about insurer practices or delays

Contact the OIC if you experience patterns of inappropriate denials or procedural violations during your appeal process.

Peer-to-Peer Review Strategy

When Aetna's initial medical necessity review results in denial, your specialist can request a peer-to-peer consultation with Aetna's medical director.

Preparation for Peer-to-Peer Call

Clinical Talking Points:

  • FCS rarity (approximately 1 in 1 million prevalence)
  • Genetic confirmation with specific mutations identified
  • Quantified triglyceride levels and pancreatitis frequency
  • Failed response to maximum tolerated standard therapies
  • Waylivra's unique antisense mechanism targeting APOC3 mRNA

Supporting Data to Reference:

  • APPROACH trial efficacy data (57% triglyceride reduction)
  • European real-world evidence from post-marketing use
  • Safety monitoring protocols for thrombocytopenia risk
  • Patient-specific treatment goals and monitoring plan

Scheduling and Logistics

  • Request peer-to-peer within 72 hours of denial notification
  • Provide 2-3 time windows for medical director availability
  • Prepare concise case summary (1-2 pages) highlighting key clinical points
  • Have patient's complete medical record accessible during call

External Review Through Washington OIC

Washington's external review process provides an independent assessment of medical necessity denials when internal appeals are unsuccessful.

Eligibility and Process

Who can request external review:

  • Washington residents with fully-insured health plans (including Aetna commercial plans)
  • Denials based on medical necessity, appropriateness, or coverage terms
  • Completed internal appeal process with final adverse determination

Submission Requirements:

  • Written request to insurer within 60 days of final internal denial
  • Copy of denial letters from all internal appeal levels
  • Additional clinical evidence supporting medical necessity
  • Patient authorization for medical record release

IRO Review Process

The assigned Independent Review Organization will:

  • Review complete medical record and insurer's denial rationale
  • Consider current medical evidence and professional guidelines
  • Evaluate appropriateness of coverage criteria for rare conditions
  • Issue binding decision within 20 days (expedited: 72 hours)

Successful external review outcomes require:

  • Clear documentation of FCS diagnosis and severity
  • Evidence of standard treatment inadequacy or contraindications
  • Specialist attestation of medical necessity for Waylivra specifically
  • Demonstration that denial criteria are inappropriately restrictive for rare disease

Costs and Patient Support Options

Manufacturer Support Programs

Ionis Pharmaceuticals may offer patient assistance programs for eligible patients. Contact their patient support services to inquire about:

  • Financial assistance applications
  • Insurance navigation support
  • Clinical trial information for investigational access

Foundation Grants and Resources

Organizations that may provide assistance for rare disease medications:

  • National Organization for Rare Disorders (NORD): Patient assistance programs
  • HealthWell Foundation: Copay assistance for qualifying conditions
  • Patient Advocate Foundation: Insurance appeals support and financial aid

State-Specific Resources

Washington residents have access to:

  • Washington Healthplanfinder: Marketplace plan comparison and enrollment assistance
  • Apple Health (Medicaid): Expanded coverage for qualifying low-income residents
  • Prescription Drug Assistance Programs: State-sponsored medication access programs

Frequently Asked Questions

How long does Aetna's medical necessity review take in Washington? Standard review typically takes 30-45 days from complete submission. Expedited review (for urgent cases like recent pancreatitis) must be completed within 72 hours.

What if Waylivra is completely excluded from my Aetna formulary? Non-formulary status requires a medical necessity exception rather than standard prior authorization. The appeal process is more comprehensive but still achievable with proper clinical documentation.

Can I request expedited appeal if my triglycerides are extremely high? Yes. Triglyceride levels >1,000 mg/dL or recent pancreatitis episodes qualify for expedited review with appropriate clinical urgency documentation from your specialist.

Does Washington's external review process cost anything? No. External review through Washington's OIC is free to patients. The insurer pays all IRO fees, and the decision is binding on Aetna if the review is favorable.

What happens if my employer plan is self-insured? Self-insured ERISA plans may not be subject to Washington state external review laws. However, many employers voluntarily provide external review processes, and federal ERISA appeals procedures still apply.

How do I find a lipid specialist familiar with FCS in Washington? Contact major medical centers like University of Washington Medical Center or Seattle Children's Hospital. The National Lipid Association also maintains a specialist directory.

Can I continue working during the appeal process? Yes, but if you're currently on Waylivra through another source (international access, clinical trial), discuss continuity of care options with your specialist to avoid treatment interruptions.

What documentation should I keep during the appeal process? Save all correspondence, denial letters, submission confirmations, and appeal decisions. Create a timeline of all communications and maintain copies of clinical records submitted.

About Counterforce Health: Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals through evidence-backed strategies. The platform analyzes denial letters, identifies specific coverage criteria, and drafts targeted rebuttals using appropriate clinical evidence and payer-specific workflows. For complex cases like Waylivra appeals, Counterforce Health can help streamline the medical necessity documentation process and improve approval outcomes.

Sources & Further Reading

This article is for informational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage determinations and treatment decisions. Appeal rights and timelines may vary by plan type and state regulations.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.